INTERCEPT PHARMACEUTICALS IN (ICPT) Forecast, Price Target & Analyst Ratings

NASDAQ:ICPT • US45845P1084

Current stock price

19 USD
+0.04 (+0.21%)
At close:
19 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INTERCEPT PHARMACEUTICALS IN (ICPT).

Forecast Snapshot

Consensus Price Target

Price Target
$19.38
+ 2.00% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Feb 29, 2024
Period
Q4 / 2023
EPS Estimate
$0.03
Revenue Estimate
92.785M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
70.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$19.38
Upside
+ 2.00%
From current price of $19.00 to mean target of $19.38, Based on 20 analyst forecasts
Low
$19.19
Median
$19.38
High
$19.95

Price Target Revisions

1 Month
6.63%
3 Months
24.59%

Price Target Summary

20 Wall Street analysts provided a forecast for the next 12 months for ICPT. The average price target is 19.38 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 19.
The average price target has been revised upward by 24.59% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ICPT Current Analyst RatingICPT Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

ICPT Historical Analyst RatingsICPT Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
70.00%
ICPT was analyzed by 20 analysts. The buy percentage consensus is at 70. So analysts seem to be have mildly positive about ICPT.
In the previous month the buy percentage consensus was at a similar level.
ICPT was analyzed by 20 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-09-27RBC CapitalMaintains Sector Perform -> Sector Perform
2023-09-27B. Riley SecuritiesDowngrade Buy -> Neutral
2023-09-27Canaccord GenuityDowngrade Buy -> Hold
2023-09-27HC Wainwright & Co.Downgrade Buy -> Neutral
2023-08-03Canaccord GenuityMaintains Buy -> Buy
2023-08-03HC Wainwright & Co.Reiterate Buy
2023-07-13HC Wainwright & Co.Upgrade Sell -> Buy
2023-06-29Canaccord GenuityUpgrade Hold -> Buy
2023-06-26RBC CapitalMaintains Sector Perform -> Sector Perform
2023-06-15RBC CapitalMaintains Sector Perform -> Sector Perform
2023-05-30B. Riley SecuritiesMaintains Buy -> Buy
2023-05-23NeedhamDowngrade Buy -> Hold
2023-05-23Canaccord GenuityMaintains Hold -> Hold
2023-05-23B of A SecuritiesMaintains Underperform -> Underperform
2023-05-22RBC CapitalReiterate Sector Perform -> Sector Perform
2023-05-22BairdMaintains Outperform -> Outperform
2023-05-22HC Wainwright & Co.Downgrade Neutral -> Sell
2023-05-18Raymond JamesDowngrade Outperform -> Market Perform
2023-04-28Raymond JamesMaintains Outperform
2023-04-10Piper SandlerMaintains Overweight
2023-03-06Raymond JamesMaintains Outperform
2023-03-03NeedhamMaintains Buy
2023-03-03RBC CapitalMaintains Sector Perform
2023-03-03SVB LeerinkMaintains Market Perform
2023-02-15RBC CapitalMaintains Sector Perform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Feb 29, 2024
Period
Q4 / 2023
EPS Estimate
$0.03
Revenue Estimate
92.785M
Revenue Q2Q
20.16%
EPS Q2Q
105.54%
Number of Analysts
17

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.01%
EPS (1 Month)
0.00%
EPS (3 Months)
660.22%

Next Earnings Summary

ICPT is expected to report earnings on 2/29/2024. The consensus EPS estimate for the next earnings is 0.03 USD and the consensus revenue estimate is 92.78M USD.
The next earnings revenue estimate has been revised upward by 0.01% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2030

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
ICPT revenue by date.ICPT revenue by date.
312.7M
24.09%		260.75M
-16.61%		285.71M
9.57%		337.77M
18.22%		368.48M
9.09%		368.73M
0.07%		370.63M
0.52%		354.64M
-4.31%		344.04M
-2.99%		287.77M
-16.36%		334.33M
16.18%
EBITDA
YoY % growth
ICPT ebitda by date.ICPT ebitda by date.
-215.48M
30.21%		-97.876M
54.58%		-67.624M
30.91%		-45.877M
32.16%		103M
324.51%		47.371M
-54.01%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
ICPT ebit by date.ICPT ebit by date.
-218.6M
30.03%		-100.69M
53.94%		-68.216M
32.25%		-45.946M
32.65%		102.71M
323.54%		107.98M
5.13%		116.5M
7.89%		101.85M
-12.58%		97.124M
-4.64%		33.03M
-65.99%		43.142M
30.61%
Operating Margin
ICPT operating margin by date.ICPT operating margin by date.
-69.91%-38.62%-23.88%-13.60%27.87%29.28%31.43%28.72%28.23%11.48%12.90%
EPS
YoY % growth
ICPT eps by date.ICPT eps by date.
-7.97
26.81%		-3.41
57.21%		6.04
277.13%		-1.33
-122.07%		2.09
256.55%		1.77
-15.32%		1.70
-3.79%		1.65
-3.16%		1.56
-5.00%		0.43
-72.39%		0.58
34.66%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth		0.03
105.54%		0.20
125.62%		0.51
461.59%		0.61
657.77%		0.65
2,259.76%		0.29
49.43%		0.37
-27.06%		0.27
-55.58%		0.15
-76.89%
Revenue
Q2Q % growth		92.785M
20.16%		83.794M
23.30%		92.679M
10.70%		94.418M
6.34%		97.074M
4.62%		N/AN/AN/AN/A
EBITDA
Q2Q % growth		1.663M
109.56%		8.14M
125.81%		32.303M
565.46%		39.627M
1,967.14%		45.492M
2,635.54%		N/AN/AN/AN/A
EBIT
Q2Q % growth		3.596M
119.99%		11.722M
137.06%		27.099M
480.66%		33.435M
1,937.48%		36.89M
925.86%		N/AN/AN/AN/A

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ICPT Yearly Revenue VS EstimatesICPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
ICPT Yearly EPS VS EstimatesICPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10 -15

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-33.62%
EPS Next 5 Year
-22.89%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
4.21%
Revenue Next 5 Year
1.71%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
46.24%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

INTERCEPT PHARMACEUTICALS IN / ICPT Forecast FAQ

What is the average price target for INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

20 analysts have analysed ICPT and the average price target is 19.38 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 19.

Can you provide the upcoming earnings date for INTERCEPT PHARMACEUTICALS IN?

INTERCEPT PHARMACEUTICALS IN (ICPT) will report earnings on 2024-02-29, after the market close.

What are the consensus estimates for INTERCEPT PHARMACEUTICALS IN (ICPT) next earnings?

The consensus EPS estimate for the next earnings of INTERCEPT PHARMACEUTICALS IN (ICPT) is 0.03 USD and the consensus revenue estimate is 92.78M USD.

What is the consensus rating for INTERCEPT PHARMACEUTICALS IN (ICPT) stock?

The consensus rating for INTERCEPT PHARMACEUTICALS IN (ICPT) is 70 / 100 . This indicates that analysts generally have a neutral outlook on the stock.